A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Recurrent|Metastatic Breast Cancer ( HER2 Negative)
Interventions: DRUG: Eribulin mesylate
Sponsor: Eisai Inc.